Gregory R Wade Ph.D. Email & Phone Number

West Palm Beach, Fl, Us

EXUMA Biotech is a clinical-stage biotechnology company discovering and developing cell and gene therapies for solid & liquid tumors.Cell therapy has already delivered remarkable on-target responses to certain hematological malignancies through a complex manufacturing process. Through our tumor metabolism regulated (TMR) CAR-T and CAR-TaNK platforms, we are taking cellular therapies to the next step by harnessing the power of the immune system to target some of the most challenging solid tumor malignancies and building delivery platforms that may enable more patients to access cell & gene therapies in the future.

West Palm Beach, Fl, Us

Waltham, Massachusetts, Us

About Danforth AdvisorsDanforth Advisors is the financial backbone to hundreds of life science companies, providing integrated and scalable consulting teams ranging from staff accountant through CFO. The company’s services span the full breadth of a finance organization’s needs, whether short or long term, including accounting and operational finance support, capital raising, financial planning and analysis, IPO preparation, post-public SEC compliance, clinical business operations management and strategic and operational human resources. Founded in 2011, Danforth has been a strategic and trusted thought partner to more than 650 life science companies, private and public, across all stages of the corporate life cycle. The company is headquartered in Waltham, Massachusetts with additional operations in metropolitan New York, the mid-Atlantic region and the West Coast. Additional information is available at www.danforthadvisors.com.

San Francisco, California, Us

Sunnyvale, Ca, Us

Lead the business development efforts at Pharmacyclics.

Los Angeles, California, Us

Sellside equity analyst focused on emerging pharmaceutical companies and the BioDefense sector. Equity research lead coverage of Anacor (ANAC), Avanir (AVNR), Cubist (CBST), Celldex (CLDX), Delcath (DCTH), Durata (DRTX), Epizyme (EPZM), Endocyte (ECYT), Fibrocell (FCSC), Insmed (INSM), Ironwood (IRWD), Macrogenics (MGNX), Novavax (NVAX), Oncogenex (OGXI), Oncolytics (ONCY), Oncothyreon (ONTY), Pharmacyclics (PCYC), Regulus (RGLS), Spectral Medical (SDI), SIGA, Zalicus (ZLCS).

Los Angeles, California, Us

Sellside equity analyst focused on emerging pharmaceutical companies and the BioDefense sector. Equity research coverage of Adolor (ADLR), Anacor (ANAC), Avanir (AVNR), Amicus (FOLD), Biomimetic (BMTI), Cleveland Biolabs (CBLI), Cubist (CBST), Clinical Data (CLDA), Celldex (CLDX), Cytokinetics (CYTK), Delcath (DCTH), Emergent BioSolutions (EBS), Halozyme (HALO), Immunomedics (IMMU), Ironwood (IRWD), Medicinova (MNOV), Neurogesx (NGSX), Oncogenex (OGXI), Poniard (PARD), Pharmacyclics (PCYC), SIGA, Xenoport (XNPT), Zalicus (ZLCS).

Us

Equity Analyst following emerging pharmaceutical companies. Research coverage on Adolor (ADLR), Avigen (AVGN), Biomimetic (BMTI), Cubist (CBST), CombinatoRx (CRXX), Cytokinetics (CYTK), Dynavax (DVAX), Amicus (FOLD), Neurogesx (NGSX), Novacea (NOVC), Poniard (PARD), Pharmacyclics (PCYC), Pharmion (PHRM), Palatin (PTN), Replidyne (RDYN), Middlebrook (MBRK), Trubion (TRBN), Targacept (TRGT), Xenoport (XNPT), Zymogenetics (ZGEN)

Us

Supported the Senior Research Analyst, and Head of Research, Thomas Dietz

Carlsbad, Ca, Us

Briefly assisted the executive management team in evaluating potential commercial partnering strategies for the Company's advanced Crohn's therapeutic candidate ISIS-2302 prior to the drug's Phase III failure and corporate restructuring.

Lead the Company's Corporate and Investor communications efforts, and business development activities leading to the successful partnering of the excessive scarring dermatology product candidate Fibrostat with Biovail.

Focussed on private development staged emerging pharmaceutical and life-science focussed venture-backed businesses.

Ph.D., Physiology

Hon. B.Sc., Medical Biophysics

Ontario Secondary School Diploma, Science, General Arts